SCHEMBL3048432

SCHEMBL3048432

COC(=O)C(Cc1ccccc1)Nc1nc2nonc2nc1Nc1ccc(Cl)c(Cl)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 3/20 0.46
FPR2 P25090 1/20 0.45
PTGS2 P35354 1/20 0.44
DHODH Q02127 1/20 0.42
ELANE P08246 1/20 0.41
PYGL P06737 1/20 0.41
MAPT P10636 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
TP53 P04637 2/20 0.41
CCR2 P41597 1/20 0.41
CCR5 P51681 1/20 0.41
ATM Q13315 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
NOS3 P29474 1/20 0.40
NOS1 P29475 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3048435 1.00 NOS2 (0.46) NOS2FPR2PTGS2DHODHELANE
SCHEMBL5534949 0.83 FPR2 (0.46) FPR2DHODHMAPTSMN1; SMN2TP53
SCHEMBL3052199 0.78 MAPT (0.46) DHODHMAPTSMN1; SMN2TP53CCR2
SCHEMBL3045625 0.74 MEN1 (0.45) DHODHMAPTSMN1; SMN2TP53CCR2
SCHEMBL3051396 0.74 TP53 (0.55) MAPTSMN1; SMN2TP53CCR2CCR5
SCHEMBL5539670 0.73 MAPT (0.45) DHODHMAPTSMN1; SMN2TP53CCR2
SCHEMBL4415553 0.72 NOS2 (0.58) NOS2FPR2ATMNOS3NOS1
SCHEMBL7674471 0.72 NOS2 (0.58) NOS2FPR2ATMNOS3NOS1
SCHEMBL4415551 0.72 NOS2 (0.58) NOS2FPR2ATMNOS3NOS1
SCHEMBL3054891 0.71 MAPT (0.49) MAPTSMN1; SMN2TP53CCR2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100222356-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2010-09-02 US claimed
US-20090131445-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-05-21 US claimed
EP-1799689-A1 FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS Compass Pharmaceuticals LLC (US) 2007-06-27 EP claimed
WO-2006044402-A1 FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS COMPASS PHARMACEUTICALS LLC (US) 2006-04-27 WO claimed
US-20100222356-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2010-09-02 US disclosed
US-20090131445-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents COMPASS PHARMACEUTICALS LLC (US) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100222356-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents CDC73, VHL, RB1 NOS2 3224/4885FPR2 567/4885PTGS2 1548/4885
US-20090131445-A1 Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents CDC73, RB1, CA5A NOS2 2457/4885FPR2 703/4885PTGS2 949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.